Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Context Therapeutics Inc.NASDAQ: CNTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $2.33M rose 12.7% year over year, ahead of the +9.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.6% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +8.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.33M+18.6% QoQ
Last fiscal yearDec 2025
$7.85M+8.6% YoY
LTMMar 2026
$8.11M+9.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.7%-100.0%-112.7 pp
1 year+8.6%-100.0%-108.6 pp
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
7.85M USD
Year-over-year change
+8.6%
4-year CAGR
+21.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.0% is the 2nd highest of 11, against a peer median of -18.3%.
  • Over three fiscal years its annual growth of +0.2% compares with a peer median of -6.9%.
CNTX Competitors
Selling, General & Admin for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.75M USD-6.4%-9.4%347.5%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$23.29M USD-40.2%-9.5%—
IMAImageneBio IncLTM Mar 2026$21.2M USD-9.1%-2.3%—
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$15.32M USD-41.8%+90.0%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.48M USD+21.4%-17.7%—
CNTXContext Therapeutics Inc.LTM Mar 2026$8.11M USD+9.0%+0.2%—
CLNNClene Inc.LTM Mar 2026$7.9M USD-34.1%-17.0%5897.0%
Peer median (excluding CNTX) —-18.3%-6.9%3816.8%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.